Caffeine: Neuroprotective functions in cognition and Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 23, Issue 5, 2008, Pages 417-422

  Rosso, Andi ^a,b   Mossey, Jana ^b   Lippa, Carol F ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY   (United States)

Author keywords

Adenosine receptors; Aging; Alzheimer's disease; Caffeine; Cognition; Epidemiology; Risk factors

Indexed keywords

ACETYLCHOLINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; AMYLOID BETA PROTEIN; CAFFEINE;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CHOLINERGIC SYSTEM; COFFEE; COGNITION; COGNITIVE DEFECT; DRUG MECHANISM; ENVIRONMENTAL FACTOR; HUMAN; LONG TERM MEMORY; NEUROPROTECTION; NONHUMAN; PREVALENCE; RECEPTOR BLOCKING; REVIEW; RISK FACTOR;

EID: 54049151578     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317508320083     Document Type: Review

References (33)

1. Sloane PD, Zimmerman S., Suchindran C., et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health. 2002 ; 23: 213-231.
2. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord. 2008 ; 23: 888-895.
3. Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson's disease. Arch Neurol. 2007 ; 64: 576-580.
4. Rudolphi KA, Keil M., Fastbom J., Fredholm BB Ischaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci Lett. 1989 ; 103: 275-280.
5. Popoli P., Blum D., Martire A., Ledent C., Ceruti S., Abbracchio MP Functions, dysfunctions and possible therapeutic relevance of adenosine A2a receptors in Huntington's disease. Prog Neurobiol. 2007 ; 81: 331-348.
6. Bjorklund O., Kahlstrom J., Salmi P., et al. The effects of methylmercury on motor activity are sex- and age-dependent, and modulated by genetic deletion of adenosine receptors and caffeine administration. Toxicology. 2007 ; 241: 119-133.
7. Ritchie K., Carriere I., De Mendonca A., et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology. 2007 ; 69: 536-545.
8. Jarvis MJ Does caffeine intake enhance absolute levels of cognitive performance. Psychopharmacology. 1993 ; 110: 45-52.
9. Johnson-Kozlow M., Kritz-Silverstein D., Barrett-Connor E., Morton D. Coffee consumption and cognitive function among older adults. Am J Epidemiol. 2002 ; 156: 842-850.
10. Maia L., De Mendonca A. Does caffeine intake protect from Alzheimer's disease ? Eur J Neurol. 2002 ; 9: 377-382.
11. van Gelder BM, Buijsse B., Tijhuis M., et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr. 2007 ; 61: 226-232.
12. Lindsay J., Laurin D., Verreault R., et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002 ; 156: 445-453.
13. Tyas SL, Manfreda J., Strain LA, Montgomery PR Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol. 2001 ; 30: 590-597.
14. Van Boxtel MPJ, Schmitt JAJ, Bosma H., Jolles J. The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacol Biochem Behav. 2003 ; 75: 921-927.
15. Fredholm BB, Battig K., Holmen J., Nehlig A., Zvartau EE Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999 ; 51: 83-133.
16. Ribeiro JA, Sebastiao AM, De Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol. 2003 ; 68: 377-392.
17. de Mendonça A., Sebastião AM, Ribeiro JA Adenosine: does it have a neuroprotective role after all ? Brain Res Rev. 2000 ; 33: 258-274.
18. Dall'Igna OP, Fett P., Gomes MW, Souza DO, Cunha RA, Lara DR Caffeine and adenosine A 2a receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol. 2007 ; 203: 241-245.
19. Dall'Igna OP, Porciuncula LO, Souza DO, Cunha RA, Lara DR Neuroprotection by caffeine and adenosine A2a receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol. 2003 ; 138: 1207-1209.
20. Prediger RDS, Batista LC, Takahashi RN Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats: Involvement of adenosine A1 and A2a receptors. Neurobiol Aging. 2005 ; 26: 957-964.
21. Haas HL, Selbach O. Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 ; 362: 375-381.
22. Svilaas A., Sakhi AK, Andersen LF, et al. Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans. J Nutr. 2004 ; 134: 562-567.
23. Jacobson KA, von Lubitz Dkje, Daly JW, Fredholm BB Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci. 1996 ; 17: 108-113.
24. Meyer PT, Elmenhorst D., Boy C., et al. Effect of aging on cerebral A1 adenosine receptors: A [18F] CPFPX PET study in humans. Neurobiol Aging. 2007 ; 28: 1914-1924.
25. Arendash GW, Schleif WS, Rezai-Zadeh K., et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience. 2006 ; 142: 941-952.
26. Angulo E., Casado V., Mallol J., et al. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer's disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 2003 ; 13: 440-451.
27. Acquas E., Tanda G., Di Chiara G. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacol. 2002 ; 27: 182-193.
28. Karadsheh N., Kussie P., Linthicum DS Inhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives. Toxicol Lett. 1991 ; 55: 335-342.
29. Carter AJ, O'Connor WT, Carter MJ, Ungerstedt U. Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors. J Pharmacol Exp Ther. 1995 ; 273: 637-642.
30. Shi D., Nikodijevic O., Jacobson KA, Daly JW Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. Cell Mol Neurobiol. 1993 ; 13: 247-261.
31. Rees K., Allen D., Lader M. The influences of age and caffeine on psychomotor and cognitive function. Psychopharmacology. 1999 ; 145: 181-188.
32. Riedel WJ, Hogervorst E., Leboux R., Verhey F., van Praag H., Jolles J. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology. 1995 ; 122: 158-168.
33. Hameleers PA, Van Boxtel MP, Hogervorst E., et al. Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Hum Psychopharmacol. 2000 ; 15: 573-581.